Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Leibniz-Institut Fur Naturstoff-Forschung Und Infektionsbiologie Ev Hans-Knoll-Institut |
| Country | Germany |
| Start Date | Nov 01, 2024 |
| End Date | Oct 31, 2028 |
| Duration | 1,460 days |
| Number of Grantees | 23 |
| Roles | Associated Partner; Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101169068 |
Microbiota medicine is the new frontier in human health. The human gastrointestinal tract is home to trillions of microbes.
Under normal conditions, these microbial communities drive physiological and homeostatic functions in the host; when altered, they can lead to severe disorders.
With an increasingly recognized role in health and disease, the gut microbiota offers promising therapeutic and diagnostic potential to tackle various pathologies (incl. metabolic, neurological, and cardiovascular disorders).
Its full clinical potential remains largely unrealized though, mostly due to the lack of critical mass capable of integrating the multiple scientific and translational dimensions of microbiota medicine.
Grounded on a team of 180leading researchers and entrepreneurs from across 12 countries and dispersed disciplines (biological big data analytics, systems and synthetic biology, experimental and translational medicine), MiCCrobioTAckle will train 12 Doctoral Candidates (DCs) with the much-needed cross-disciplinary and -sectoral expertise to advance microbiota medicine.
As course-setting disease, the DCs will focus on cancer cachexia (CC).
CC is an excellent model to study the host-microbiota axis in the context of metabolic diseases and represents the paradigm of a devastating condition in urgent need of new and more efficient means of clinical management.
Along MiCCrobioTAckle, the 12 high-calibre DCs will foster new discoveries with impact on CC, while driving scientific and technological progress in microbiota medicine in its broadest scope.
By training the next generation of researchers with out-of-the-box thinking and an entrepreneurial mindset in microbiota medicine, MiCCrobioTAckle will safeguard the EU leadership in this vanguard and imperative biotech/pharma segment, while paving the way for the development of novel gut microbiota insights and tools to tackle multiple diseases with foreseeable impact on the well-being of billions of citizens worldwide.
Universitat Rovira I Virgili; Biofaction Kg; Caelus Pharmaceuticals B.V.; Fondazione Casa Sollievo Della Sofferenza; Ruprecht-Karls-Universitaet Heidelberg; Seqbiome Ltd.; Deutsches Krebsforschungszentrum Heidelberg; Universite Catholique de Louvain; Hun-Ren Szegedi Biologiai Kutatokozpont; Snipr Biome; Friedrich-Schiller-Universität Jena; Leibniz-Institut Fur Naturstoff-Forschung Und Infektionsbiologie Ev Hans-Knoll-Institut; Stichting Amsterdam Umc; Semmelweis Egyetem; Danmarks Tekniske Universitet; Chr. Hansen As; Oslo Cancer Cluster Sa; Dnasense Aps; Ms-Omics Aps; Abzu Aps; Community Initiatives; University College Cork - National University of Ireland, Cork; Presymptom Health Ltd
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant